Previous Studies

  • A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Omecantiv Mecarbil on Mortality and Morbidity in Subjects with Chronic Heart Failure with Reduced Ejection Fraction.
  • Phase III. Randomized, Double-Blind, Multi-Center Study to Evaluate the Efficacy and Safety of Intravenous to Oral Solithromycin (CEM-101) Compared to Intravenous to Oral Moxifloxacin in the Treatment of Adult Patients with Community –Acquired Pneumonia.
  • Phase III. Strategies using XXXXX to avoid transfusions in chronic kidney disease. (START-CKD).
  • Phase III. A multinational, randomized, double-blind, placebo-controlled trial to evaluate the effect of XXXXX 90 mg twice a day on the incidence of cardiovascular death, myocardial infarction or stroke in patients with type II diabetes mellitus. THEMIS.
  • Phase IV. A Multicenter, International, Randomized, Parallel group, Double Blind, Placebo-Controlled Cardiovascular Safety & Renal Microvascular outcome with XXXXXXX, 5 mg once daily in patients with type 2 diabetes mellitus at high vascular risk. CARMELINA.
  • Phase IV. A Randomized, Placebo- Controlled, Double- Blind, Parallel Group Study to assess the Safety and Efficacy of XXX delivered via HandiHaler in COPD Subjects recovering from Hospitalization for an acute exacerbation. (Hospital Discharge Study 1).
  • A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Evaluate Cardiovascular Outcomes of XXX, 50 mg in addition to Standard of Care in Subjects with Type 2 Diabetes and with Cardiovascular Disease or Multiple Risk Factors for cardiovascular Events. TAK-875_306.
  • Phase III, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study of the Comparative Efficacy and Safety of XXX in Subjects with Acute Otitis Externa.
  • Phase II/III. Global Registry on Long-Term Oral Anti-thrombotic treatment in patients with Atrial Fibrillation Phase II and III. GLORIA.
  • Phase I/II. A Study in Japan and Ex-Japan to Characterized the Pharmacokinetic and Pharmacodynamic Response to Orteronel (XXX-700) in Chemotherapy Naïve patients with Castration-Resistant Prostate Cancer
  • Phase III. An Open Label, Randomized, Comparison of the Immunogenicity and Safety of Human Insulin Basal Bolus Regimen (XXXX 70/30) with the Sponsor Yeast based Human Insulin Basal Bolus Regimens, marketed in the United States (XXXX 70/30) in Type I Diabetes
  • Phase IV. An Open Label study to evaluate the safety. Tolerability and pharmacokinetics of XXXX in combination with other antiretrovirals (ARVs) in antiretroviral treatment-experienced HIV-1 infected subjects. TIBOTEC.
  • Phase III. Cardiovascular outcomes Study to evaluate the potential of XXXX to reduce cardiovascular risk in patients with a recent Acute Coronary Syndrome (ACS) event and type 2 diabetes mellitus (T2DM) ALECARDIO.
  • Phase III. An Open Label, 52 Week Study to Assess the Long-Term Safety of XXXX in Opioid-Induced Constipation (OIC) in Patients with Non-Cancer-Related Pain. KODIAC08.
  • Phase III. An Open Label, 52 Week Study to Assess the Long-Term Safety of XXXX in Opioid-Induced Constipation (OIC) in Patients with Cancer-Related Pain. KODIAC06.
  • Self-Medication in Cuba, Clinical Pharmacology. Dr. Alberto Zamora, Dr. Leandro Lopez, Dr. Luis A. Martinez
  • Diabetes. Diagnostic and treatment in the primary care. Dr. Luis A. Martinez., Dr. Damara Malo de Molina., Dr. Xohan Lafont
  • STD’s in adolescent patients, major risk factors, prevalence and social impact. Dr. Luis A. Martinez., Dr. Maritza Novas, Dr. Alberto Gomez